Expertise in
2
conditions

Dr. Syed Ali

Pain Medicine
Aurora Internal Medicine LTD.
North Aurora, IL 
Offers Telehealth
Expertise in
2
conditions
Aurora Internal Medicine LTD.
North Aurora, IL 

Overview

Syed Ali is a Pain Medicine provider practicing medicine in North Aurora, Illinois.

Dr. Ali is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Myositis, Macrophagic Myofasciitis, Sacroiliac Joint Disease, and Chronic Pain.

He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 8 clinical trials.

Specialties

Pain Medicine

Licenses

Anesthesiology in OH

Hospital Affiliations

Galion Community Hospital
Grand Lake Health System

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Aurora Internal Medicine LTD.
North Aurora, IL 60542
Other Locations
Western Reserve Hospital
1900 23rd St, Cuyahoga Falls, OH 44223

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
Enrollment Status: Completed
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drug: GSK1070806
Study Phase: Phase 1
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 5 Less Clinical Trials

7 Total Publications

Using qualitative system dynamics modeling to understand overdose bystander behavior in the context of Connecticut's Good Samaritan Laws and identify effective policy options.
Using qualitative system dynamics modeling to understand overdose bystander behavior in the context of Connecticut's Good Samaritan Laws and identify effective policy options.
Journal: Harm reduction journal
Published: November 30, 2023
Similar Doctors
Expertise in
10
conditions
Dr. Kenneth Candido
Pain Medicine
Expertise in
10
conditions
Dr. Kenneth Candido
Pain Medicine

Office

360 W Butterfield Rd Ste 100, 
Elmhurst, IL 
 (341.4 miles away)
630-501-1706
Languages Spoken:
English
See accepted insurances

Kenneth Candido is a Pain Medicine provider practicing medicine in Elmhurst, Illinois. Dr. Candido is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Chronic Pain, Neuralgia, Complex Regional Pain Syndrome, Laminectomy, and Knee Replacement.

Expertise in
6
conditions
Dr. Asokumar Buvanendran
Pain Medicine
Expertise in
6
conditions
Dr. Asokumar Buvanendran
Pain Medicine

University Pain Centers At RUSH

1725 W Harrison St Ste 550, 
Chicago, IL 
 (328.3 miles away)
312-942-6631
Languages Spoken:
English
See accepted insurances

Asokumar Buvanendran is a Pain Medicine provider practicing medicine in Chicago, Illinois. Dr. Buvanendran is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Acute Pain, Complex Regional Pain Syndrome, Chronic Pain, Knee Replacement, and Hip Replacement.

Expertise in
17
conditions
Dr. Timothy Lubenow
Pain Medicine
Expertise in
17
conditions
Dr. Timothy Lubenow
Pain Medicine

Office

610 S Maple Ave Ste 1500, 
Oak Park, IL 
 (333.4 miles away)
312-942-6504
Languages Spoken:
English
See accepted insurances

Timothy Lubenow is a Pain Medicine provider practicing medicine in Oak Park, Illinois. Dr. Lubenow is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Complex Regional Pain Syndrome, Chronic Pain, Neuralgia, Sacroiliac Joint Disease, and Sacral Nerve Stimulation.

Frequently Asked Questions about Dr. Syed Ali

How do I make an appointment with Dr. Syed Ali?

You can book an appointment with Dr. Syed Ali by calling their office at 630-906-1800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Syed Ali a top-rated expert for Myositis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Syed Ali is classified as an Advanced expert for Myositis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Syed Ali specialize in?

While Dr. Syed Ali is a Pain Medicine, they have specific expertise in Myositis, Macrophagic Myofasciitis, and Sacroiliac Joint Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pain Medicine.

Does Dr. Syed Ali participate in research or clinical trials?

Yes. Dr. Syed Ali has published 7 articles and abstracts on conditions like Myositis. You can view a list of Dr. Syed Ali's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Syed Ali accept my insurance?

Dr. Syed Ali accepts most major insurance plans, including Blue Cross Blue Shield and CareFirst. We recommend calling the office directly at 630-906-1800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ali's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile